Holmusk is on a mission to reimagine behavioral health and transform lives with Real-World Evidence and digital innovation. Headquartered in Singapore and New York, with offices in North Carolina, New York City, London, Malaysia and Shanghai, Holmusk generates evidence and builds digital solutions to advance behavioral health research, innovation, and care.
NeuroBlu, Holmusk's flagship product, synthesizes Real-World Data (RWD) with seamless analytic tools, enabling users to create actionable insights that drive behavioral health transformation. NeuroBlu is powered by an industry-leading and continually growing behavioral health clinical dataset, with over 20 years of data on 550,000+ patients and 20+ million encounters. Holmusk uses advanced proprietary analytics to enrich the data, with Natural Language Processing and predictive disease models designed specifically for behavioral health. Holmusk augments its data and analytic offerings with powerful digital solutions that enhance patient engagement, support disease self-management, and capture patient-reported outcomes to help guide clinical decisions and analytics. For more information, please visit www.holmusk.com.
Holmusk has raised ~$35 million in funding so far.
Founder & CEOLinkedin
Our Mission is to build world’s largest Real World Evidence (RWE) platform, starting with behavior health. At holmusk we work towards the common goal to transform healthcare by data driven medicine using digital tools.